NDATOPICALSOLUTION
Approved
Jun 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVAGARD is a topical antiseptic solution combining chlorhexidine gluconate and alcohol for skin disinfection and surgical hand scrubbing. It works as a broad-spectrum antimicrobial agent that rapidly reduces bacterial and fungal contamination on skin surfaces. Approved in 2001, it serves as a standard perioperative antiseptic in hospital and surgical settings.
LOE Approaching
As AVAGARD approaches loss of exclusivity, brand teams face consolidation pressure and should expect smaller commercial headcount and focus on generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AVAGARD offers limited career advancement potential given its LOE-approaching status and minimal active job openings (0 linked positions). Professionals joining this team should expect a focus on market defense, customer retention, and transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on AVAGARD at Solventum? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.